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LETTERS TO THE EDITOR
,B-hCG expression by bladder cancers
Sir - McLoughlin et al.'s recent paper 'Serum and urinary
levels of beta human chorionic gonadotrophin in patients
with transitional cell carcinoma' (McLoughlin, J., Pepera, T.,
Bridger, T. & Williams, G., Br. J. Cancer, 1991, 63,
822-824); was apparently prompted by my initial paper on
expression ofP-hCG by .70% of bladder cancer cell lines in
vitro (Iles et al., 1987). As such I feel their results are worthy
of further comment.
Their clinical findings were: elevated serum ,B-hCG
(>5 mIU ml-1) in only six of 62 patients with elevated
urinary levels (>25 mIU ml-') in only three. Unfortunately
the stages of disease were not fully documented in the pub-
lished paper. Of the 13-hCG positive tumour patients, five had
'poorly differentiated' tumours, one with metastatic disease,
one extravesical spread, one locally resectable tumour and
one clear on cytoscopy. The authors additionally attempted
to detect expression of P-hCG by immunohistochemically
staining 'representative' sections from 28 tumours. None was
found to be positive.
Our initial study spurred us on to look at clinical cases.
Between 1986 and 1988, pre-treatment blood and/or urine
samples were collected from 179 patients attending the Uro-
logy Department of the Royal London Hospital. Samples
were assayed for ,-hCG immunoreactivity using the in house
assay of the department of Reproductive Physiology (St Bar-
tholomew's Hospital) and classified according to the histo-
pathological staging, or clinically where the disease was
advanced. The results of this study were published in 1989
(Iles et al., 1989).
Somewhat in agreement with McLoughlin and colleagues,
we found elevated serum P-hCG (>25mIUml') in only
two of 55 patients (4%) in whom disease was limited to the
renal pelvis (Ta - T4). However, levels were substantially
elevated in 16 of 21 patients (76%) with widespread metas-
tatic disease. Furthermore, elevated urinary P-hCG was
found in four of 39 TO, 14 of 57 Ta/l, II of 25T2 - T4
patients. Grossly elevated urinary P-hCG levels were detected
in 5 of 7 metastatic disease patients.
In total agreement with McLoughlin's preliminary con-
clusions, P-hCG screening has no value as a general marker
of bladder disease. However, ,B-hCG expression is always
associated with poor prognosis. Reviewing the literature,
which dates from as early as 1904 (Djwetzi, 1904); most
reports were case studies ofadvanced stage disease. The more
recent studies, principally immunohistochemical, have
identified local tumours which expressed P-hCG. All were
poorly differentiated (more than 95% G3) and invasive (app-
roximately 60% T3 + ) (Reviewed by Iles & Chard, 1991). In
addition, such expression correlates with those local tumours
that do not respond to radiotherapy (Martin et al., 1989). It
is therefore possible that detection of P-hCG expression may
identify an aggressive phenotype which is likely to metas-
tasise.
McLoughlin et al.'s failure to detect P-hCG expression by
immunohistochemistry may, as they themselves admit, be due
to sampling error. It should be borne in mind that hCG and
free P-hCG are not stored in secretory granules, being rapidly
secreted once synthesised (Handwerger et al., 1987; Corless et
al., 1987). This may well account for the fact that positive
sections typically contain only sporadic areas ofpositive cells.
This problem was emphasised by Ryoichi Oyasu (editorial
comments to Wurzel et al., 1987) who recommended careful
study of serial tumour sections.
It still remains to be determined why normal urothelium
produce ,B-hCG in vitro (Iles et al., 1987). The possibility
arises that f3-hCG expression may be characteristic of basal
stem cells of the urothelial mucosa (Iles et al., 1990). Pro-
liferation of these cells, as in in vitro cell culture, may elicit
expression of the P-hCG gene for an unidentified function.
Ray Iles
St Bartholomew's Hospital Medical College
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